11/14
01:34 pm
cogt
Cogent Biosciences, Inc. (NASDAQ: COGT) had its price target raised by analysts at JPMorgan Chase & Co. from $19.00 to $21.00. They now have an "overweight" rating on the stock.
Low
Report
Cogent Biosciences, Inc. (NASDAQ: COGT) had its price target raised by analysts at JPMorgan Chase & Co. from $19.00 to $21.00. They now have an "overweight" rating on the stock.
11/13
08:06 am
cogt
Cogent Biosciences, Inc. (NASDAQ: COGT) had its price target lowered by analysts at Needham & Company LLC from $16.00 to $15.00. They now have a "buy" rating on the stock.
Low
Report
Cogent Biosciences, Inc. (NASDAQ: COGT) had its price target lowered by analysts at Needham & Company LLC from $16.00 to $15.00. They now have a "buy" rating on the stock.
11/13
12:45 am
cogt
Cogent Biosciences, Inc. (NASDAQ: COGT) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $11.00 price target on the stock.
Low
Report
Cogent Biosciences, Inc. (NASDAQ: COGT) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $11.00 price target on the stock.
11/12
08:00 am
cogt
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2024 Financial Results
Medium
Report
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2024 Financial Results
11/5
09:00 am
cogt
Cogent Biosciences Announces Bezuclastinib Presentations at the 66th Annual American Society of Hematology (ASH) Meeting
High
Report
Cogent Biosciences Announces Bezuclastinib Presentations at the 66th Annual American Society of Hematology (ASH) Meeting
11/4
08:19 am
cogt
Cogent Biosciences, Inc. (NASDAQ: COGT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $17.00 price target on the stock.
Medium
Report
Cogent Biosciences, Inc. (NASDAQ: COGT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $17.00 price target on the stock.
10/24
08:08 am
cogt
Cogent Biosciences, Inc. (NASDAQ: COGT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $16.00 price target on the stock.
Medium
Report
Cogent Biosciences, Inc. (NASDAQ: COGT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $16.00 price target on the stock.
10/23
07:00 am
cogt
Cogent Biosciences Announces Pipeline Expansion into KRAS and Poster Presentations at the 2024 EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics
Low
Report
Cogent Biosciences Announces Pipeline Expansion into KRAS and Poster Presentations at the 2024 EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics
10/20
09:57 am
cogt
Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation [Yahoo! Finance]
Low
Report
Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation [Yahoo! Finance]
9/30
10:51 am
cogt
Cogent Biosciences: Need To Wait For More Data For Adequate Differentiation [Seeking Alpha]
Low
Report
Cogent Biosciences: Need To Wait For More Data For Adequate Differentiation [Seeking Alpha]
9/24
12:02 pm
cogt
Cogent Biosciences, Inc. (NASDAQ: COGT) had its price target raised by analysts at Citigroup Inc. from $13.00 to $15.00. They now have a "buy" rating on the stock.
Low
Report
Cogent Biosciences, Inc. (NASDAQ: COGT) had its price target raised by analysts at Citigroup Inc. from $13.00 to $15.00. They now have a "buy" rating on the stock.
9/5
08:06 am
cogt
Cogent Biosciences, Inc. (NASDAQ: COGT) had its price target raised by analysts at Robert W. Baird from $8.00 to $10.00. They now have a "neutral" rating on the stock.
Low
Report
Cogent Biosciences, Inc. (NASDAQ: COGT) had its price target raised by analysts at Robert W. Baird from $8.00 to $10.00. They now have a "neutral" rating on the stock.
9/3
10:12 pm
cogt
Cogent Biosciences, Inc. (NASDAQ: COGT) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $11.00 price target on the stock, up previously from $10.00.
Low
Report
Cogent Biosciences, Inc. (NASDAQ: COGT) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $11.00 price target on the stock, up previously from $10.00.
9/3
11:09 am
cogt
Cogent Biosciences, Inc. (NASDAQ: COGT) had its price target lowered by analysts at HC Wainwright from $19.00 to $17.00. They now have a "buy" rating on the stock.
Low
Report
Cogent Biosciences, Inc. (NASDAQ: COGT) had its price target lowered by analysts at HC Wainwright from $19.00 to $17.00. They now have a "buy" rating on the stock.
9/3
08:00 am
cogt
Cogent Biosciences Announces Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST) Has Completed Enrollment and Advanced Past Interim Futility Analysis
Low
Report
Cogent Biosciences Announces Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST) Has Completed Enrollment and Advanced Past Interim Futility Analysis